If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My Buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA ) stock made in a Seeking Alpha post published last month—August 15th, to be precise—has already paid off. Shares have been soaring in value thisThe group is ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Despite a faltering jobs market , rising auto and student loan defaults , concerning CRE delinquencies in the Office and Multifamily spaces, and a collapsing housing sector in many regions of the country like Austin, Las Vegas, Oakland, ...

公司财务行动 - 公司于2025年9月19日以20比1的比例进行反向股票分割 旨在通过减少流通股数量提高每股价格[1] - 当前股价为1.52美元 日交易区间为1.46美元至1.585美元 年波动区间为0.131美元至3.29美元[5] - 公司市值约为1.926亿美元 日交易量为4,701,878股[5] 产品研发进展 - 公司正在推进新型双靶点融合蛋白telitacicept的三期临床开发[2] - 将在中国开展的三期研究中展示针对成人全身型重症肌无力的48周临床数据[2] - 该研究由在香港和上海证券交易所上市的合作伙伴荣昌生物制药有限公司赞助[2] 学术会议参与 - 将于2025年10月29日10:50在旧金山美国神经肌肉与电诊断医学协会年会上公布临床数据[3] - 报告标题为"Telitacicept在全身型重症肌无力患者中的疗效和安全性：三期研究结果"[3] - 公司还将参加Stifel 2025虚拟免疫与炎症论坛 包括炉边谈话和一对一投资者会议[4] 企业合作与交流 - 公司计划于2025年9月15日通过网站直播方式进行炉边谈话[4] - 通过投资者会议展现对投资者关系和信息透明度的承诺[4] - 临床数据发布被视为展示临床研究进展的关键节点[3]

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Last week, Seeking Alpha posted some takes on potential buyouts in the biotech/biopharma sector. Thursday morning, Roche ( OTCQX:RHHBY ) announced it was acquiring 89bio, Inc ( ETNB ) in a deal that could reach $3.5 billion, which inclu ...

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):   2025   2024  Revenue $ 48,867,753  $ 58,590,949  (Loss) Income Before Income Tax $ (1,896,010 ) $ 476,447  Net (Loss) Income $ (1,048,154 ) $ 483,481  Basic Earnings per Share of Common Stock $ (1.17 ) $ .54 Diluted Earnings per Share of Common Stock $ (1.17 ) $ .54 Weighted Average  Number of Shares Outstanding For Basic Earnings Per Share 894,416 894,416  Weighted Average. ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The last time I covered ProKidney (NASDAQ: PROK ), the Winston-Salem, North Carolina based biotech, for Seeking Alpha, it was July, and its share price was skyrocketing, jumping from $0.6, to >$4.5 overnight, after ...

PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that Raghu Rao, Interim Chief Executive Officer of Sonnet, will present on Thursday, September 25, 2025 at 9:40 AM PT at the MedInvest Biotech & Pharma Conference being held in Palo Alto, California. In addition to the presentation, management will be avail ...

LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. ...

Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, ...

公司战略调整 - 公司正式撤回反向股票分割提案 经过审慎考虑后决定停止该计划[1][2] - 管理层承诺通过多渠道与股东保持频繁沟通 强调专注于口服疫苗平台科学进展以创造长期股东价值[2] 业务与技术优势 - 公司专注于临床阶段口服重组疫苗研发 拥有专有递送平台技术 疫苗采用药丸形式无需冷藏储存和运输且无针刺损伤风险[3] - 技术平台适用于多种重组疫苗开发 包括现有疫苗口服版本和新适应症重组疫苗 当前研发管线涵盖冠状病毒、诺如病毒、流感预防性疫苗及HPV治疗性肿瘤免疫疫苗[3] - 已在全球提交多项专利保护 覆盖使用腺病毒和TLR3激动剂的口服疫苗接种技术[3] 企业基本信息 - 公司为临床阶段生物技术企业 股票代码OTCQX: VXRT 总部位于美国加州南旧金山[1][3] - 媒体与投资者关系由FINN Partners机构代理 指定联系人为Matt Steinberg[5]